AmbioPharm Appoints Industry Veteran Brian Gregg as CEO
CombiGene selects AmbioPharm as peptide CDMO partner for their COZY01 pain project
AmbioPharm, a Global Peptide CDMO
AmbioPharm, a provider of peptide API CDMO services, made state-of-the-art upgrades to its AmbioPharm South Carolina headquarters, including increasing synthesis capacity.
NORTH AUGUSTA, S.C.--(BUSINESS WIRE)--AmbioPharm, a worldwide leader in peptide API CDMO services, continues growth to meet capacity demands for late phase and commercial peptide production while increasing our sustainability efforts. In order to meet customer needs, we continue to make state-of-the-art upgrades to our AmbioPharm South Carolina headquarters, including increasing synthesis capacity at this location.
AmbioPharm Provides an Update on Shanghai Campus Expansion and Resumption of Customer Visits
AmbioPharm To Utilize YMC Twin-Column Chromatography in Large Scale Peptide Production
AmbioPharm to Host a Sustainable Peptide Manufacturing Workshop at Biologics 2023
Latest Publication in eLife on Non-Opioid Peptide-Based Pain Therapeutics
BERLIN, Germany and NORTH AUGUSTA, S.C., USA, 27th October 2022 – Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and systemic targeted radiation therapy of certain hard-to-treat cancers, and AmbioPharm, a global peptide contract development and manufacturing organization, today announce that they have entered into a strategic partnership for the manufacture and supply of peptide conjugates to be used by Ariceum in future clinical studies.